Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adipose-derived autologous stem cell therapy - U.S. Stem Cell

Drug Profile

Adipose-derived autologous stem cell therapy - U.S. Stem Cell

Alternative Names: AdipoCell (Bioheart); Bioheart Acute Cell Therapy; Implanted autologous adipose-derived stem cells - U.S. Stem Cell; LipiCell

Latest Information Update: 28 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioheart
  • Developer Magnum Cell Therapies; Revita Life Sciences; U.S. Stem Cell
  • Class Anti-ischaemics; Cardiovascular therapies; Erectile dysfunction therapies; Eye disorder therapies; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Intervertebral disc degeneration
  • Phase I/II Heart failure
  • No development reported Chronic obstructive pulmonary disease; Coronary disorders; Erectile dysfunction; Meniscus disorders; Myocardial infarction; Myocardial ischaemia; Osteoarthritis; Peripheral ischaemia; Psoriasis

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Meniscus disorder in USA (Injection)
  • 28 Feb 2021 No recent reports of development identified for clinical-Phase-Unknown development in Psoriasis in Unknown (IV)
  • 19 Oct 2020 Tissue Genesis has been acquired by Orgenesis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top